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Glioblastoma (GBM) is the most malignant human brain tumour, characterized by rapid progression, invasion, intense
angiogenesis, high genomic instability, and resistance to therapies. Despite countless experimental researches for new
therapeutic strategies and promising clinical trials, the prognosis remains extremely poor, with a mean survival of less than 14
months. GBM aggressive behaviour is due to a subpopulation of tumourigenic stem-like cells, GBM stem cells (GSCs), which
hierarchically drive onset, proliferation, and tumour recurrence. The morbidity and mortality of this disease strongly encourage
exploring genetic characteristics of GSCs. Here, using array-CGH platform, we investigated genetic and genomic aberration
proﬁles of GBM parent tumour (n = 10) and their primarily derived GSCs. Statistical analysis was performed by using R
software and complex heatmap and corrplot packages. Pearson correlation and K-means algorithm were exploited to compare
genetic alterations and to group similar genetic proﬁles in matched pairs of GBM and derived GSCs. We identiﬁed, in both
GBM and matched GSCs, recurrent copy number alterations, as chromosome 7 polysomy, chromosome 10 monosomy, and
chromosome 9p21deletions, which are typical features of primary GBM, essential for gliomagenesis. These observations suggest
a condition of strong genomic instability both in GBM as GSCs. Our ﬁndings showed the robust similarity between GBM mass
and GSCs (Pearson corr ≥0 65) but also highlighted a marked variability among diﬀerent patients. Indeed, the heatmap
reporting Gain/Loss State for 21022 coding/noncoding genes demonstrated high interpatient divergence. Furthermore, K-means
algorithm identiﬁed an impairment of pathways related to the development and progression of cancer, such as angiogenesis, as
well as pathways related to the immune system regulation, such as T cell activation. Our data conﬁrmed the preservation of the
genomic landscape from tumour tissue to GSCs, supporting the relevance of this cellular model to test in vitro new target
therapies for GBM.
1. Introduction
Glioblastoma (GBM) is the most common malignant pri-
mary tumour of the central nervous system (CNS). The
standard ﬁrst-line management for this cancer consists in
maximum surgical resection, but its ability to deeply inﬁltrate
makes complete resection quite impossible. GBM is charac-
terized by rapid progression and invasion, cell inﬁltration,
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intense angiogenesis, resistance to radio- and chemother-
apies, and high frequency of relapse. This aggressive behav-
iour is responsible for the poor prognosis, with a median
survival of about 14 months and a 5-year survival rate of
5.1% [1]. GBM resistance to therapies and the high frequency
of recurrence are mainly due to a subpopulation of tumouri-
genic stem-like cells, known as GBM stem cells (GSCs), able
to hierarchically initiate, maintain, and spread the neoplasm.
GSCs are self-renewing, pluripotent, highly proliferative, and
genetically unstable. Unlike normal stem cells, which acquire
a quiescence after DNA damage, GSCs express a plethora of
proteins that promote cell survival [2].
Despite the advances in the GBM biology knowledge,
comprising behaviour, molecular features, and the heteroge-
neous genetic landscape, only few targeted therapies have
been developed and applied in clinics [3–5]. However, an
increasing number of studies that exploit genomic
approaches have identiﬁed genetic markers typical of glioma
and useful for diagnosis. These evidence led the World
Health Organization to introduce new diagnostic guidelines
based upon molecular diagnosis in 2016 (WHO) [6]. There-
fore, nowadays, GBMs are distinguished in IDH-wildtype or
IDH-mutated, depending on the presence of recurrent hot-
spot mutations in isocitrate dehydrogenases IDH1 and
IDH2. Notably, large sample studies reported that IDH
mutation is found in the majority of secondary GBMs
(70-80%) and only rarely in primary GBMs [7]. GBMs are
well characterized also from an epigenetic point of view and
the DNA-hypermethylated phenotype, called CpG island
methylator phenotype (CIMP), has been correlated to a good
prognosis [8]. In particular, the most established improve-
ment in predicting GBM patients’ outcome is the methyla-
tion of the O6-Methylguanine-DNA methyltransferase
(MGMT) promoter, which has been associated to a positive
response to temozolomide [9, 10]. However, the constant
improvement in genetic characterization of GBMs is still fail-
ing to be translated to clinical practice, suggesting that other
discovery paradigms should be considered. At DNA level,
GBMs are usually characterized by high levels of genomic
instability. The GBM genome shows many copy number
alterations (CNAs) that have been catalogued by computa-
tional methodologies [11–13]. These studies collectively have
identiﬁed frequently ampliﬁed genes such as EGFR, MET,
PDGFRA, MDM2, PIK3CA, CDK4, and CDK6 and deleted
genes including CDKN2A/B, PTEN, and RB1. During the
last years, array comparative genomic hybridization
(array-CGH) has successfully contributed to improve the
detection rate of genomic unbalances and alterations in can-
cer and to correlate recurrent CNAs to cancer pathomechan-
isms and prognosis [14, 15]. Considering the importance of
CNA data, we focused on the comparison between genetic
and genomic aberration proﬁles of GBM tumour masses
and their primarily derived GSCs, investigating if GSC popu-
lation harbours typical alterations diﬀerent from the tumour
bulk. Since GSCs are widely exploited in in vitro disease stud-
ies, uncovering dissimilarities with the corresponding
tumour masses could be useful to set more reliable GBM
models and to test new potential targeted therapies that could
be eﬀective also on the cell populations that are therapy
resistant. In order to address these questions, we analysed
recurrent hotspot mutations and performed array-CGH to
compare CNAs between GBM and their derived GSCs at
whole genome level.
2. Materials and Methods
2.1. Study Population. Ten GSCs were derived from matched
primary (n = 9) and recurrent (n = 1) GBMs provided by the
Neurosurgery Unit of the Fondazione IRCCs Ca’ Granda
Ospedale Maggiore Policlinico (Milan), according to the eth-
ical requirements of the institutional committee on human
experimentation.
Patients recruited between January 2014 and May 2016
were randomly included in the study, after informed consent
was signed. The histological analyses were based on the 2016
WHO criteria for CNS tumours [3]. Demographic and clini-
cal data are reported in Table 1.
2.2. GBM Sample Collection. GBM sample processing was
performed as previously reported [16]. Brieﬂy, after each
surgical intervention, the tumour specimen was collected
and maintained in Dulbecco’s modiﬁed Eagle’s medium:
Nutrient Mixture F-12 (DMEM/F12, Thermo Fisher,
Waltham, Massachusetts) containing 1% penicillin/strep-
tomycin (Thermo Fisher) at 4°C, for up to 24 h. An ali-
quot of tissue was ﬁxed in a 4% paraformaldehyde
(PFA) solution (Sigma-Aldrich, Basel, Switzerland) in
Dulbecco’s phosphate-buﬀered saline (D-PBS) and subse-
quently embedded in paraﬃn (Sigma-Aldrich). Another ali-
quot was ﬁrstly mechanically minced with a surgical scalpel
and then enzymatically digested with 0.625Wu/mL Liberase
Blendzyme 2 (Roche, Mannheim, Germany) for 1 h at 37°C
[17]. A cell suspension was obtained after passing dissociated
through a 0.70μm pore size ﬁlter (Thermo Fisher).
2.3. Primary GSC Isolation. GSCs were isolated as previously
described [17]. Brieﬂy, GBM cells were cultured in the appro-
priate medium for isolation of GSCs, consisting of
DMEM/F12 supplemented with 20ng/mL epidermal growth
factor (EGF) (R&D Systems, Minneapolis, USA), 10ng/mL
ﬁbroblast growth factor-2 (bFGF) (PeproTech Inc., Rocky
Hill, NY, USA), and 1% penicillin/streptomycin. Cells were
cultured in a humidiﬁed incubator with 5% CO2, 5% O2 at
37°C, and split once a week. At each passage (P), GSC neuro-
spheres were dissociated with Tryple Select (Gibco, Grand
Island, NY, USA) and Trypan Blue dye exclusion assay
(Gibco) was used to assess cell viability. Cells were routinely
observed with an inverted phase-contrast microscope (Nikon
Eclipse TE300; Nikon, Shinjuku, Tokyo, Japan), and images
were acquired with a digital camera (Zeiss Axiovision, Zeiss,
Oberkochen, Germany).
2.4. Immunophenotypic Analyses. Flow cytometric analyses
were performed to assess the immunophenotypic proﬁle of
GSCs. The assay was conducted as previously described
[17]. Brieﬂy, each GSC line (5 × 104 cell/tube) was incubated
with phycoerythrin- (PE-) or ﬂuorescein isothiocyanate-
(FITC-) conjugated antibody to rate the expression of the
following stemness/progenitor cell markers: CD15, CD31,
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CD45, CD133 (Miltenyi Biotec, Bisley, Surrey, UK), and
CD90 (Millipore Temecula, CA, USA). Notably,
7-aminoactinomycin D (7-AAD, BD) was added to each tube
to exclude dead cells from the analysis. After an incuba-
tion of 30min at room temperature, washing and ﬁxation
with 4% PFA, immunomarked GSCs were scanned on a
ﬂuorescence-activated cell sorting (FACS) ﬂow cytometer
and analysed by CellQuest software (BD Biosciences, San
Jose, CA). FlowJo software (Tree Star Inc., Ashland) was
used to perform postprocessing analyses.
2.5. DNA Isolation.DNA from the FFPE tumour samples was
obtained using a Biostic FFPE tissue DNA isolation kit
(MO BIO Laboratories, Carlsbad, CA, USA), following man-
ufacturer’s instructions. DNA extraction was performed from
FFPE tissue sections with at least 70% of tumour content,
assessed by hematoxylin/eosin staining. DNA was extracted
from GSCs, at a passage ranging from P4 and P10, using
the QIAamp DNA Micro Kit (Qiagen, Hilden, Germany),
according to manufacturer’s protocol.
2.6. IDH1, IDH2, and TERT Mutation Analysis. The assess-
ment of hotspot mutations in IDH1, IDH2, and TERT pro-
moter was performed as previously described [18]. In brief,
DNA was ampliﬁed by multiplexed primer mix targeting
codon 132 and 172 of IDH1 and IDH2, respectively, and
position c.-124 and c.-146 of TERT promoter. PCR, SAP,
and IPLEX reactions were conducted as described in manu-
facturer’s protocol (Agena Bioscience, San Diego, CA, USA).
Samples were transferred to a SpectroCHIP (Agena
Bioscience, San Diego, CA, USA) and analysed by mass spec-
trometry. The spectral proﬁles generated by MALDI-TOF
mass spectrometry were evaluated using Typer v.4.0 software
(Agena Bioscience, San Diego, CA, USA).
2.7. MGMT Promoter Methylation Evaluation. MGMTmeth-
ylation was assessed both in FFPE tumour tissue and GSCs.
DNA was modiﬁed with sodium bisulﬁte using the EZ
DNA Methylation-Gold Kit (Zymo Research Corp., Irvine,
CA). The methylation analysis was implemented as
previously described [10, 19]. PCR was performed on at least
20 ng of bisulﬁte-treated DNA and about 10 pmol primers.
Quantitative DNA methylation analysis was carried out on
the Pyro Mark ID instrument using Pyro Gold Reagents
(Qiagen) and 1pmol of sequencing primer. Methylation data
were analysed by the Q-CpG software v1.9 (Qiagen) and the
levels of methylation of each sample are represented by the
mean of the methylation percentages at each CpG site of
the investigated region.
2.8. Array-CGH. Array-CGH analysis was performed as pre-
viously described [19], using 60-mer oligonucleotide probe
technology (SurePrint G3 Human CGH 8× 60K, Agilent
Technologies, Santa Clara, CA, USA), according to manufac-
turer’s instructions. Agilent Feature Extraction was exploited
to generate raw data, which were further analysed using
Cytogenomics 2.7 with the ADAM-2 algorithm (Agilent
Technologies, Santa Clara, CA, USA). In order to increase
the accuracy of the results, the Diploid Peak Centralization
algorithm was applied. A minimum of three consecutive pro-
bes/region was considered as ﬁlter. The threshold for geno-
mic deletion is x = −1; the threshold for genomic gain is
x = +0 58. Notably, in a mosaic scenario, the threshold is
between -1 and 0 for deletions and between 0 and +0.58 for
duplications [20]. Ampliﬁcations and homozygous deletions
are considered with threshold >+2 and <-1, respectively.
Variants reported as population variants in the public data-
bases were not listed. Genomic coordinates are according to
the build 37 assembly (March 2009) of the Human Genome
Reference consortium (GRch37/hg19).
2.9. Statistical Analysis. Statistical analysis has been per-
formed by using R software and complex heatmap [21] and
corrplot packages (https://github.com/taiyun/corrplot) were
exploited to ﬁgure out the data. Pearson correlation was used
to compare genetic alteration proﬁles in matched pairs of
GBM and derived GSCs. In order to group similar genetic
proﬁles among samples, K-means algorithm was performed.
Moreover, we used the chi-square test to compare MGMT
methylation levels of GBM with the matched GSC sam-
ples. GO-Term enrichment analysis was developed using
WebGestalt (http://www.webgestalt.org/option.php).
3. Results
3.1. Clinical Features of Patients Aﬀected by GBM. Our GBM
cohort has an even proportion of male and female patients
with a mean age at diagnosis of 59 years (ranging from 36
to 82 years old). All tumours had been examined and classi-
ﬁed according to the WHO guidelines and all GBMs were
IDH-wildtype; GBM of patient (Pt) 3 is the ﬁrst relapse.
The observed overall survival (OS), in terms of time between
the date of surgery and the date of death, varies between 2
and 54 months, with a mean value of 14.2 and a median value
of 11.5 months. The Karnofsky Performance Score (KPS) was
performed during hospitalization, before surgery, and
assessed between 60% and 90%. As a cellular marker for pro-
liferation, the Ki-67 protein was evaluated by immunohisto-
chemistry, in a range between 15% and 70%.
Table 1: Clinicopathological characteristics of the patients enrolled
in the study.
Patient ID Sex Age (yrs) Dx OS KPS Ki67
Pt 2 M 60 GBM 4 60% 15%
Pt 3 F 50 GBM(R) 16 70% 40%
Pt 9 F 82 GBM 5 60% 15%
Pt 10 F 63 GBM 5 90% 35%
Pt 15 M 36 GBM 54 80% 60%
Pt 33 F 65 GBM 11 90% 70%
Pt 56 M 75 GBM 2 60% 40%
Pt 60 M 49 GBM 16 80% 70%
Pt 85 M 59 GBM 12 80% 30%
Pt 90 F 58 GBM 17 90% 30%
Pt: patient; M: male; F: female; yrs: years; Dx: diagnosis; R: relapse; OS:
overall survival expressed in months; KPS: Karnofsky Performance Score.
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3.2. GSCs Diﬀer in Stemness Marker Expression. About 30%
of GSC lines experienced both an adherent and a ﬂoating
phase (GSC 15, GSC 33, and GSC 56), still maintaining stem-
ness properties (Figure 1(a)). Notably, estimating the number
of viable cells from P0 to P6 (30 days), we observed diﬀerent
growth rates, thus each GSC line shows a speciﬁc prolifera-
tion curve, anyhow growing with an exponential rate
(Figure 1(b)). Analysing GSCs, at a passage ranging from
P4 to P10, by ﬂow cytometry, we determined the expression
of CD133, CD90, CD15, CD31, and CD45 as stem/progeni-
tor cell markers, reporting diﬀerent expression patterns
among patients. As shown in Table 2, all the investigated
stemness markers were expressed in our GSCs, with CD90
as the highest one. Notably, performing ﬂow cytometry at
higher passages, we observed that marker expression
remains rather stable in 90% of GSCs, with a variability of
about 5-10%.
3.3. Recurrent Hotspot Alterations. We investigated the
most frequently reported genetic alterations for GBM
IDH-wildtype in all GBM-GSC-matched couples at a passage
ranging from P4 to P10, as in correspondence of the ﬂow
cytometric analysis. The presence of the hotspot mutations
c.-124C>T and c.-146C>T in the promoter region of TERT
was evaluated. As shown in Table 3, 8 out of 10 tumours were
mutated in TERT, 6 harboured the c.-124C>T mutation (Pt
2, Pt 10, Pt 15, Pt 56, Pt 85, and Pt 90), while 2 had the
c.-146C>T mutation (Pt 9 and Pt 60). For all samples, the
same alteration found in the GBM was present also in the
GSCs, conﬁrming the driver function of these mutations.
Moreover, the high prevalence of mutated cases in our small
cohort of patients is concordant with the one reported by
previous large studies on GBM IDH-wildtype [22, 23], fur-
ther corroborating the relevance of such marker in this type
of glioma.
We analysed theMGMT promoter methylation, which is
the principal prognostic factor in primary GBM [24]. One
out of 10 GBMs (Pt 90) was substantially hypermethylated
at this promoter region, while Pt 10, Pt 15, and Pt 33 were
only partially methylated; the remaining GBMs were non-
methylated (Table 3). Analogously to TERT mutations, the
methylation levels of MGMT promoter were fairly con-
cordant between GBM and GSCs of each patient. Partic-
ularly, nonmethylated GBMs showed nonmethylated GSCs.
Regarding the methylated cases, Pt 10 and Pt 33 showed
almost equal methylation percentages in the two compo-
nents, considering the 5% of sensitivity limitation of the
pyrosequencing technique [25], while Pt 15 and Pt 90 dis-
played more diﬀerent values (p value = 1.12% for Pt 15 and
1.96% for Pt 90). In particular, Pt 90 showed an increment
in methylation in GSCs (86% vs. 58% in the tumour,
Table 3), which could be explained considering that GBM
is more heterogeneous and nonneoplastic cells could par-
tially alter the methylation level. Conversely, GSC 15 methyl-
ation is lower than GBM 15 (14% vs. 31% in the tumour,
Table 3). In order to deepen the diﬀerences in methylation
levels in Pt 15 and Pt 90, we veriﬁed the presence of deletions
encompassing the MGMT locus (on chromosome 10q26.3)
(Table 3) and both GBM 90 and GSC 90 exhibited a
monosomy of chromosome 10 with a mosaic distribution.
It means that not all cells harbour a deletion of one MGMT
allele and that the heterogeneity is more evident in tumour
bulk. However, Pt 15 displays deletions of MGMT with a
mosaic pattern only in the GBM component, while the GSCs
have no genomic aberration at this locus, which could par-
tially explain the lower methylation levels in GSCs (Table 3).
3.4. Array-CGH Proﬁles. Array-CGH experiments conﬁrmed
the robust similarity between GBM mass and GSCs of each
case (Figure 2) but also highlighted a marked variability
among diﬀerent cases. Common alterations, present in
almost all tumours, were polysomy of chromosome 7, mono-
somy of chromosome 10, and homozygous 9p21 deletion.
To measure the genomic relationship between GBM and
derived GSCs, we performed Pearson correlation metric
(Figure 3(a)). The mean Pearson correlation is 0.43, range
-0.23/+1. By setting the correlation threshold to 0.65 (calcu-
lated from our data considering the mean correlation added
to the standard deviation), we found that all patients, except
for Pt 3, Pt 15, and Pt 56, showed a good correlation (Pearson
correlation≥ 0.65), denoting the concordance between GBM
and matched GSC.
Notably, Pt 3 and Pt 56 had, respectively, Pearson corr.
values of 0.58 and 0.64, thus below the threshold, but fairly
close to it, whereas Pt 15 Pearson correlation was 0.36, cor-
roborating the mentioned increase in dissimilarity between
GBM and GSCs for this patient, which is already appreciable
from the genome view reported in Figures 2 and 3(a).
Moreover, we obtained the p values of our correlation
metric using cor.mtest function in R that performs the signif-
icance test for each pair of correlations; p values < 0.05
indicate a signiﬁcant correlation between samples. Notably,
all p values resulted <0.05, showing a signiﬁcant correlation
between GBM and GSC of each patient, also for Pt 15.
Noteworthy, Pt 15 has the lowest number of genomic
aberrations among our cohort. This could be related to his
long-term survival (OS 54 months), signiﬁcantly higher than
the mean GBM OS (14.2 months) and to his young age
(36 yrs, with respect to the GBM patient median age of
59 yrs). Unfortunately, the fact that Pt 15 is the only patient
with these characteristics, due to the great rarity of such
high OS cases, prevented further considerations about his
genomic pattern.
To further assess the intrapatient and interpatient corre-
lation, we investigated the distribution of CNAs (gains and
losses) in GBM and GSCs along genes (coding and noncod-
ing). As reported in Figure 3(b), except Pt 15, all
GBM-GSC-matched pairs are clustered together, highlight-
ing the strong correspondence of GBM and GSCs in each
patient. This analysis also quite demonstrated the divergence
between GBM and GSCs of Pt 15, further corroborating the
abovementioned considerations.
Taken together, the data show an increment of alterations
in GSCs than in GBM, i.e., GSC 90 at chromosomes 4, 17,
and 18 compared to the matched GBM 90 (Figure 1).
Therefore, to deepen the comparison of GBM and
GSCs, we decided to focus on copy number patterns of
well-characterized genetic markers in primary GBMs that
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could be also exploited for the development of new treat-
ments: EGFR, PDGFRA, MDM4, and MET ampliﬁcation
and CDKN2A, PTEN, and NFKB1 deletions (Table 3).
We highlighted that our cohort of patients almost
completely recapitulates the information reported in litera-
ture, ensuring that not selection biases were made.
All of our samples, except again Pt 15, displayed a com-
plete polysomy of chromosome 7, encompassing both EGFR
and MET genes. The chromosome 7 polysomy is considered
a fundamental event driving GBM tumourigenesis. Indeed, it
was present in almost all GBMs and derived GSCs together
with the monosomy of chromosome 10, encompassing the
PTEN locus and the focal deletion of chromosome 9p21 sur-
rounding CDKN2A [26–29]. Regarding EGFR, it was further
substantially ampliﬁed in 5 out of 10 samples (Pt 3, Pt 15, Pt
33, Pt 56, and Pt 60), comprehending also Pt 15 that had only
the focal ampliﬁcation of EGFR locus in both GBM and
GSCs. It is noteworthy that 3 out of 5 EGFR-ampliﬁed
GSC 2 GSC 3 GSC 9 GSC 10 GSC 15
GSC 33 GSC 56 GSC 60 GSC 85 GSC 90
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Figure 1: GSC isolation and propagation. (a) Representative images of GSCs of each patient, captured at passage 5. Magniﬁcation 10x with an
inverted phase-contrast microscope. (b) Proliferation curves of GSCs. Each passage was done every 5 days.
Table 2: Stemness marker analyses in GSCs revealed diﬀerent
expression patterns among GBM patients.
Sample Passage CD15 CD31 CD34 CD45 CD133 CD90
GSC 2 10 + +++ + + +++ +++
GSC 3 4 + +++ + + +++ +
GSC 9 4 + +++ ++ + + +
GSC 10 4 + + + ++ + +++
GSC 15 4 + ++ ++ + ++ +++
GSC 33 4 ++ + ++ ++ +++ +++
GSC 56 4 + + + + ++ +++
GSC 60 5 + + ++ + + +++
GSC 85 4 + ++ ++ + ++ ++
GSC 90 6 + + + +++ +++ +++
+: 0-33%; ++: 34-66%; +++: 67-100%.
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Figure 2: Genome view of GBM and GSCs of each patient displaying high intrapatient similarity and interpatient discordance. Gains or losses
of chromosomal regions are computed by comparing signal intensity in GBM and GSCs with the background signal of the reference and then
applying a segmenting and smoothing algorithm. Line plots show chromosomal changes seen in GBMs; the y-axis indicates the log2 value
ranging from -5 to 5; blue indicates gain/ampliﬁcations, red losses/deletions.
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GBM lost this marker in the derived GSCs (Pt 3, Pt 33, and Pt
56). Moreover, none of the samples had MET ampliﬁcation,
further supporting the rarity of this condition [4]. As for
the polysomy of chromosome 7, almost all GBMs and GSCs
harboured monosomy of chromosome 10, thus at least one
allele of PTEN is deleted in all GBMs and matched GSCs,
conﬁrming the driver function of this alteration in glioma-
genesis [26–29].
Another marker present in almost all samples was the
deletion of chromosome 9p21 involving CDKN2A. It was
present at homozygous status in the majority of patients,
with some discordance between GBM and GSC, probably
due to the heterogeneity of the samples, such as for GBM
56. Remarkably, Pt 3, the relapse sample, exhibited two oppo-
site patterns of alteration at this locus in his GBM and GSCs,
del and gain, respectively, (Table 3).
Finally, the other markers were present each in only one
sample, conﬁrming the low frequency of these alterations,
particularly, Pt 9 (GBM and GSCs) lost NFKB1 in a mosaic
pattern and displayed the ampliﬁcation of PDGFRA. Pt 33
(GBM and GSCs) instead was the only sample with MDM4
ampliﬁcation.
3.5. Clustering of Similar Genetic CNA Proﬁles in GBM and
GSC Samples. In order to further evaluate the genetic pat-
terns, we used K-means algorithm to ﬁnd genes with similar
proﬁles among samples. We chose k = 12 because it maxi-
mizes the variance interclusters and minimizes the variance
intracluster (Supplementary Material (available here)).
Results are shown in Figure 4, reporting the average genetic
alteration proﬁle line for each cluster. All clusters seemed to
proﬁle randomly among samples, except clusters 5, 7, and
8. Cluster 5 (grey area and grey line in Figures 4(a) and
4(b), respectively) contains 1091 genes (including EGFR),
which were ampliﬁed on average in all samples, except
GBM 90. Clusters 7 (purple area and line in Figures 4(a)
and 4(b)) and 8 (pink area and line in Figures 4(a) and
4(b)) contain, respectively, 27 and 856 genes (encompassing
CDKN2A and PTEN, respectively), which were deleted in
about 90% of samples.
We performed GO-Term enrichment analysis using
WebGestalt tool to investigate the pathways of genes
involved in these aberrations and found that there is an
impairment of pathways related to cancer development
and progression (Supplementary Material). In particular,
we identiﬁed clear distinctive pathways included in the
three clusters analysed. In cluster 5, we identiﬁed genes
involved in the new vessel formation and in nitrogen
and oxygen response. In cluster 7, the main identiﬁed
pathways are related to the immune response as “regula-
tion of cytokine-mediated signaling pathway,” whereas in
cluster 8, we identiﬁed genes associated at two distinctive
pathways, metabolic process pathway and interestingly
brain development.
4. Discussion
GBM is highly heterogeneous and resistant to conventional
chemo- and radiotherapies and several recent studies sug-
gested that it is driven and maintained by GSCs. The devel-
opment of more personalized therapies is still urgent and
in vitro models able to reliably recapitulate the original
tumour are yet under discussion. Here, we focused on the
characterization of the genomic patterns of GBM masses
and respective isolated GSCs in 10 primary GBM patients
to additionally establish the reliability of GSCs as in vitro
model and to search for genetic features typical of GSCs
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Figure 3: Hierarchical clustering results in our cohort of 10 patients highlighted the intrapatient similarity. (a) Correlation map reporting
Pearson correlation values for each comparison. The bar on the left of the map indicates the color legend of the Pearson corr. values
calculated for each couple of samples in the matrix. (b) Heatmap reporting Gain/Loss State for 21022 coding/noncoding genes (y-axis) in
all samples (x-axis). Red and blue colors represent, respectively, losses and gains.
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and able to explain the resistance and aggressiveness of
these cells.
Remarkably, the characterization of primary GSCs in the
analysed cases revealed patient-speciﬁc proﬁles, both in
terms of growth rate and surface stemness marker expres-
sion. Particularly, we observed a high interpatient variability
and a peculiar immunophenotypic proﬁle in each GSC pop-
ulation, in accordance with the well-known heterogeneity of
GBMs [30]. Interestingly, our cytoﬂuorimetric analysis
revealed that all GSCs were all positive, but at diﬀerent levels,
for the markers of stemness and endothelial progenitors:
CD15, CD133, CD90, CD31, and CD45.
Although some authors have demonstrated that in vitro
growth of GSCs and their stemness marker expression repre-
sents a signiﬁcant predictor of clinical outcome [31–33], the
real association between the biological features of GSCs and
GBM proﬁle has yet to be established.
From a genomic perspective, the typical genetic features
of primary GBMs were markedly concordant between
GBM/GSC couples, conﬁrming the high similarity between
the tumour mass and its respective GSC population. Regard-
ing TERT mutations, 8 out of 10 GBMs and matched GSC
cases were mutated in the promoter region. Of note, TERT
mutations have a prognostic role in gliomas, being a negative
prognostic factor in primary GBM withoutMGMTmethyla-
tion [34]. In our cohort, two cases were methylated at the
MGMT promoter (Pt 15 and Pt 90), but unfortunately, the
number of samples included prevented the possibility to
perform statistically signiﬁcant analyses about the link
between TERT promoter mutations, MGMT methylation,
and patients’ survival. Nevertheless, this was beyond the pur-
poses of this study. The almost similar levels of MGMT pro-
moter methylation between GBM and GSCs suggested that
also this epigenetic marker is conserved in the GSC popula-
tion, which is usually responsible for the high frequency of
recurrence in this type of tumour. This evidence is in accor-
dance with the fact that generally the level of methylation
between primary GBMs and respective relapses is fairly com-
parable [35]. Moreover, the increased methylation levels of
GSC 90 could be explained by the fact that it is a more homo-
geneous sample than the whole GBM mass [3]; in addition, a
sample heterogeneity cannot be excluded, as already sug-
gested [3, 36]. Conversely, the decreased methylation level
in GSC 15 compared to GBM 15 could be due to the
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Figure 4: K-means results to cluster similar genetic CNA proﬁles in our GBM and GSC samples in 12 groups. (a) Pie chart reporting the
number of genes gathered in each cluster according to K-means algorithm. (b) Centroid proﬁles for each cluster. Each line depicts the
intracluster CNA mean values among samples (x-axis). Grey line represents the cluster 5 proﬁle, containing genes ampliﬁed in all patients
except GBM 90. Purple and pink lines are referred to clusters 7 and 8, containing genes deleted in all samples except for GSC 3 and GSC 56.
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absence of deletions at this locus. Nevertheless, the methyla-
tion levels in both GSC 15 and GSC 90, along with the pres-
ence of mosaic deletions of MGMT in GSC 90, suggest that
also the GSC population is heterogeneous and not all cells
are MGMT methylated.
Almost all GBM and GSC couples had polysomy of chro-
mosome 7, monosomy of chromosome 10 (PTEN), and dele-
tions at chromosome 9p21 (CDKN2A) that are typical
features of primaryGBM, essential for gliomagenesis and usu-
ally conserved in the whole GBM mass [13, 26, 28, 29, 37].
The only two patients showing diﬀerent patterns of these
markers between GBM and GSCs were Pt 3 and Pt 15.
Pt 3 showed opposite molecular features at the 9p21
region between GBM (9p21 loss) and GSCs (9p21 gain).
This GBM is the ﬁrst tumour recurrence, meaning that
the patient had been already treated and this could have
aﬀected the genomic conﬁguration of the GBM and/or
GSCs, although the Pearson corr. is quite close to the
threshold of 0.65. Another possible mechanism to explain
the peculiar molecular proﬁle of Pt 3 could be the “parallel
evolution” model proposed by Baysan et al. [26]. By this
theory, diﬀerent clones could evolve separately from a
common ancestor, giving rise independently to fairly equal
genomic patterns between primary and recurrent tumours.
Pt 15 is the only young long-term survival patient
included in the study and he has substantially less genomic
aberration both in GBM and in GSCs. In details, Pt 15
showed the ampliﬁcation of EGFR without the polysomy of
the chromosome 7 in both GBM and GSCs, the monosomy
of chromosome 10 only in GSCs, and the deletion of
CDKN2A in a mosaic fashion in GSCs. The asset of these
GBM peculiar markers in long-term GBM survivors is still
discussed; therefore, it is quite complex to deﬁne their associ-
ation with overall survival [1, 38–40].
Regarding EGFR ampliﬁcation, 5 out of 10 analysed cases
exhibit this alteration in GBM, but only 2 of them retained it
in GSC population. This could be due to the negative selec-
tive pressure induced by EGF addition to the medium, as
described by [41, 42]. However, this phenomenon is still con-
troversial; indeed, not all GSCs derived from EGFR-ampliﬁed
GBM lack the ampliﬁcation of this marker, as reported in
several studies [43–45].
The polysomy of chromosome 7 involves also the MET
locus, which is never ampliﬁed in our cohort, neither in the
cases without EGFR ampliﬁcation. Indeed, MET is usually
overexpressed in mesenchymal/proneural subgroup of
GBMs EGFR-wildtype and PTEN-lost [46], thus conﬁguring
as an alternate way to deregulate the tyrosine kinase signaling
pathway. Other alternative mechanisms to impair the signal-
ing pathway mediated by tyrosine kinases are the PDGFRA
ampliﬁcation and the NFKB1A deletion [4, 47].
Pt 9 displayed a normal pattern of EGFR and harbours
both PDGFRA ampliﬁcation and NFKB1A deletion in GBM
and GSCs. Finally, only GBM and GSCs of Pt 33 harboured
MDM4 ampliﬁcation that is an alternative and quite infre-
quent route to inactivate p53 [4].
Therefore, almost all samples show concordance between
GBM and GSCs, as demonstrated by the Pearson correlation
analysis (Pearson corr ≥0 65), corroborating the fact that
GSCs resemble their parental tumour at a genomic level
[45, 48]. Besides this, the heatmap highlights the interpatient
variability between GBM and GSC, further supporting the
high heterogeneous behaviour of this type of tumour.
The slight intrapatient genomic diﬀerences between
GBM and GSCs, and particularly the partial enrichment of
alterations in GSCs, could be related to the heterogeneity of
GBM and that some low frequent alterations could be
masked by the presence of nonneoplastic cells in the analysed
specimens. Nevertheless, the presence of these dissimilarities
could also be due to the in vitro growing conditions of GSCs.
Indeed, even if diﬀerent GSCs did not acquire in vitro identi-
cal genomic alterations under the same selective pressure, it
is anyway possible that in vitro culture could select small sub-
populations of cells in the parental GBM mass harbouring
alterations not detectable in the tumour bulk. Moreover, it
was recently demonstrated that discordant inheritance of
chromosomal and extrachromosomal DNA elements
between primary tumour mass, neurosphere cultures, and
xenografts exists and is strictly related to the dynamic GBM
evolution [44]. Therefore, on the one side, elevated concor-
dance between GSCs and the primary tumour masses corrob-
orates the use of these as reliable in vitro and in vivo models
of GBM; on the other side, the dissimilarities could be useful
to understand clonal evolution of the tumour and to test new
targeted treatments. Indeed, the K-means algorithm identi-
ﬁed three clusters of genes equally altered among the GBM
and GSC samples. These three clusters involved the already
described genes EGFR, CDKN2A, and PTEN. However,
besides these loci, GO-term enrichment analysis pointed
out defects in other genes, with similar CNA proﬁles among
GBM/GSC couples, encompassing pathways essential for the
development and progression of cancer, such as pathway
related to angiogenesis, as well as pathways related to the
immune system regulation. This last point is particularly
interesting, considering the promising advances in
immunotherapies.
Despite the limitation of our work, related to the small
number of patients analysed, our ﬁndings contribute to add
a little piece to the complicated puzzle of GBM. The detailed
analyses of genomic aberrations in GSCs further testify
that they represent a good model since they maintain the
main genetic markers of GBM. Indeed, as GSCs are
patient-speciﬁc and radio- and chemoresistant, they repre-
sent a challenging target for therapies. In the era of preci-
sion medicine, indeed, a better understanding of the GSC
molecular landscape is pivotal to design eﬀective target
therapies for GBM.
Data Availability
The data used to support the ﬁndings of this study are
available from the corresponding author upon request.
Conflicts of Interest
The authors declare that there is no conﬂict of interest
regarding the publication of this paper.
10 Stem Cells International
Authors’ Contributions
Chiara Pesenti and Stefania Elena Navone contributed
equally to this work.
Acknowledgments
We would like to show our gratitude to the Fondazione
Floriani which, with great competence and humanity, has
been a professional guide and a valid support for our patients
in all the complex phases from diagnosis to therapy. We are
also immensely grateful to A-Tono: The World in Your
Hand and to Dr. Giuseppe Caspani for the precious help in
communication strategy with dissemination of our research
activity. The research was funded by the Italian Ministry of
Health Regione Lombardia Ricerca Finalizzata 2011-2012,
RF-2011-02347106 (PI Monica Miozzo), and by the Italian
Ministry of Health, RC2015/2016 (PI Giovanni Marﬁa).
The study was also carried out by the support of Fondazione
Floriani and A-Tono: The World in Your Hand.
Supplementary Materials
Supplementary Material: an Excel File in which there are
reported lists of genes included in n = 12 clusters, grouped
by K-means algorithm, with the relative location, values,
and GO-Term enrichment analysis performed by WebGes-
talt. Moreover, all the output ﬁles achieved by WebGestalt
are included. (Supplementary Materials)
References
[1] K. Wipﬂer, A. S. Cornish, and C. Guda, “Comparative molec-
ular characterization of typical and exceptional responders in
glioblastoma,” Oncotarget, vol. 9, no. 47, pp. 28421–28433,
2018.
[2] T. J. Abou-Antoun, J. S. Hale, J. D. Lathia, and S. M.
Dombrowski, “Brain cancer stem cells in adults and chil-
dren: cell biology and therapeutic implications,” Neurother-
apeutics, vol. 14, no. 2, pp. 372–384, 2017.
[3] A. Sottoriva, I. Spiteri, S. G. M. Piccirillo et al., “Intratumor
heterogeneity in human glioblastoma reﬂects cancer evolu-
tionary dynamics,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 110, no. 10,
pp. 4009–4014, 2013.
[4] The Cancer Genome Atlas Research Network, “Comprehen-
sive genomic characterization deﬁnes human glioblastoma
genes and core pathways,” Nature, vol. 455, pp. 1061–1068,
2008.
[5] W. Wick, S. Dettmer, A. Berberich et al., “N2M2 (NOA-20)
phase I/II trial of molecularly matched targeted therapies plus
radiotherapy in patients with newly diagnosed non-MGMT
hypermethylated glioblastoma,” Neuro-Oncology, vol. 21,
no. 1, pp. 95–105, 2018.
[6] D. N. Louis, A. Perry, G. Reifenberger et al., “The 2016 World
Health Organization classiﬁcation of tumors of the central
nervous system: a summary,” Acta Neuropathologica,
vol. 131, no. 6, pp. 803–820, 2016.
[7] H. Yan, D. W. Parsons, G. Jin et al., “IDH1 and IDH2 muta-
tions in gliomas,” The New England Journal of Medicine,
vol. 360, no. 8, pp. 765–773, 2009.
[8] J. A. Holmes, A. K. Paulsson, B. R. Page et al., “Genomic pre-
dictors of patterns of progression in glioblastoma and possible
inﬂuences on radiation ﬁeld design,” Journal of Neuro-Oncol-
ogy, vol. 124, no. 3, pp. 447–453, 2015.
[9] M. Esteller, J. Garcia-Foncillas, E. Andion et al., “Inactivation
of the DNA-repair gene MGMT and the clinical response of
gliomas to alkylating agents,” The New England Journal of
Medicine, vol. 343, no. 19, pp. 1350–1354, 2000.
[10] L. Fontana, S. Tabano, E. Bonaparte et al., “MGMT-methy-
lated alleles are distributed heterogeneously within glioma
samples irrespective of IDH status and chromosome 10q dele-
tion,” Journal of Neuropathology & Experimental Neurology,
vol. 75, no. 8, pp. 791–800, 2016.
[11] C. H. Mermel, S. E. Schumacher, B. Hill, M. L. Meyerson,
R. Beroukhim, and G. Getz, “GISTIC2.0 facilitates sensitive
and conﬁdent localization of the targets of focal somatic
copy-number alteration in human cancers,” Genome Biology,
vol. 12, no. 4, article R41, 2011.
[12] R. Beroukhim, G. Getz, L. Nghiemphu et al., “Assessing the
signiﬁcance of chromosomal aberrations in cancer: methodol-
ogy and application to glioma,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 104,
no. 50, pp. 20007–20012, 2007.
[13] R. Wiedemeyer, C. Brennan, T. P. Heﬀernan et al., “Feedback
circuit among INK4 tumor suppressors constrains human
glioblastoma development,” Cancer Cell, vol. 13, no. 4,
pp. 355–364, 2008.
[14] V. Rausch, A. Krieg, J. Camps et al., “Array comparative geno-
mic hybridization of 18 pancreatic ductal adenocarcinomas
and their autologous metastases,” BMC Research Notes,
vol. 10, p. 560, 2017.
[15] H. S. Patmore, J. N. E. Ashman, N. D. Staﬀord et al., “Genetic
analysis of head and neck squamous cell carcinoma using
comparative genomic hybridisation identiﬁes speciﬁc aberra-
tions associated with laryngeal origin,” Cancer Letters,
vol. 258, no. 1, pp. 55–62, 2007.
[16] L. Guarnaccia, S. E. Navone, E. Trombetta et al., “Angiogenesis
in human brain tumors: screening of drug response through a
patient-speciﬁc cell platform for personalized therapy,” Scien-
tiﬁc Reports, vol. 8, article 8748, 2018.
[17] G. Marﬁa, R. Campanella, S. E. Navone et al., “Autocrine/para-
crine sphingosine-1-phosphate fuels proliferative and stem-
ness qualities of glioblastoma stem cells,” Glia, vol. 62,
no. 12, pp. 1968–1981, 2014.
[18] C. Pesenti, L. Paganini, L. Fontana et al., “Mass
spectrometry-based assay for the molecular diagnosis of gli-
oma: concomitant detection of chromosome 1p/19q codele-
tion, and IDH1, IDH2, and TERT mutation status,”
Oncotarget, vol. 8, no. 34, pp. 57134–57148, 2017.
[19] D. Ronchetti, K. Todoerti, G. Tuana et al., “The expression
pattern of small nucleolar and small Cajal body-speciﬁc
RNAs characterizes distinct molecular subtypes of multiple
myeloma,” Blood Cancer Journal, vol. 2, no. 11, pp. e96–
e98, 2012.
[20] R. Valli, C. Marletta, B. Pressato et al., “Comparative genomic
hybridization on microarray (a-CGH) in constitutional and
acquired mosaicism may detect as low as 8% abnormal cells,”
Molecular Cytogenetics, vol. 4, no. 1, p. 13, 2011.
[21] Z. Gu, R. Eils, and M. Schlesner, “Complex heatmaps reveal
patterns and correlations in multidimensional genomic data,”
Bioinformatics, vol. 32, no. 18, pp. 2847–2849, 2016.
11Stem Cells International
[22] P. J. Killela, Z. J. Reitman, Y. Jiao et al., “TERT promoter muta-
tions occur frequently in gliomas and a subset of tumors
derived from cells with low rates of self-renewal,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 110, no. 15, pp. 6021–6026, 2013.
[23] P. J. Killela, C. J. Pirozzi, P. Healy et al., “Mutations in IDH1,
IDH2, and in the TERT promoter deﬁne clinically distinct sub-
groups of adult malignant gliomas,” Oncotarget, vol. 5, no. 6,
pp. 1515–1525, 2014.
[24] K. Masui, P. S. Mischel, and G. Reifenberger, “Molecular clas-
siﬁcation of gliomas,” Handbook of Clinical Neurology, Vol.
134, 97–120, 2016.
[25] A. C. Tsiatis, A. Norris-Kirby, R. G. Rich et al., “Comparison of
Sanger sequencing, pyrosequencing, and melting curve analy-
sis for the detection of KRASmutations: diagnostic and clinical
implications,” The Journal of Molecular Diagnostics, vol. 12,
no. 4, pp. 425–432, 2010.
[26] M. Baysan, K. Woolard, M. C. Cam et al., “Detailed longitudi-
nal sampling of glioma stem cells in situ reveals Chr7 gain and
Chr10 loss as repeated events in primary tumor formation and
recurrence,” International Journal of Cancer, vol. 141, no. 10,
pp. 2002–2013, 2017.
[27] P. J. Cimino, Y. Kim, H. J. Wu et al., “Increased HOXA5
expression provides a selective advantage for gain of whole
chromosome 7 in IDH wild-type glioblastoma,” Genes &
Development, vol. 32, no. 7-8, pp. 512–523, 2018.
[28] I. Crespo, A. L. Vital, A. B. Nieto et al., “Detailed characteriza-
tion of alterations of chromosomes 7, 9, and 10 in glioblasto-
mas as assessed by single-nucleotide polymorphism arrays,”
The Journal of Molecular Diagnostics, vol. 13, no. 6, pp. 634–
647, 2011.
[29] P. Tunici, L. Bissola, E. Lualdi et al., “Genetic alterations and
in vivo tumorigenicity of neurospheres derived from an adult
glioblastoma,” Molecular Cancer, vol. 3, no. 1, p. 25, 2004.
[30] N. S. Bayin, A. S. Modrek, and D. G. Placantonakis, “Glioblas-
toma stem cells: molecular characteristics and therapeutic
implications,” World Journal of Stem Cells, vol. 6, no. 2,
pp. 230–238, 2014.
[31] R. Pallini, L. Ricci-Vitiani, N. Montano et al., “Expression of
the stem cell marker CD133 in recurrent glioblastoma and its
value for prognosis,” Cancer, vol. 117, no. 1, pp. 162–174, 2011.
[32] F. Zeppernick, R. Ahmadi, B. Campos et al., “Stem cell marker
CD133 aﬀects clinical outcome in glioma patients,” Clinical
Cancer Research, vol. 14, no. 1, pp. 123–129, 2008.
[33] B. H. Kong, J. H. Moon, Y. M. Huh et al., “Prognostic value of
glioma cancer stem cell isolation in survival of primary glio-
blastoma patients,” Stem Cells International, vol. 2014, Article
ID 838950, 6 pages, 2014.
[34] H. Arita, K. Yamasaki, Y. Matsushita et al., “A combination of
TERT promoter mutation andMGMTmethylation status pre-
dicts clinically relevant subgroups of newly diagnosed glioblas-
tomas,” Acta Neuropathologica Communications, vol. 4, no. 1,
pp. 79–93, 2016.
[35] A. A. Brandes, E. Franceschi, A. Paccapelo et al., “Role of
MGMTmethylation status at time of diagnosis and recurrence
for patients with glioblastoma: clinical implications,” The
Oncologist, vol. 22, no. 4, pp. 432–437, 2017.
[36] D. Sciuscio, A. C. Diserens, K. van Dommelen et al., “Extent
and patterns ofMGMTpromotermethylation in glioblastoma-
and respective glioblastoma-derived spheres,” Clinical Cancer
Research, vol. 17, no. 2, pp. 255–266, 2011.
[37] R. G. W. Verhaak, K. A. Hoadley, E. Purdom et al., “Integrated
genomic analysis identiﬁes clinically relevant subtypes of glio-
blastoma characterized by abnormalities in PDGFRA, IDH1,
EGFR, and NF1,” Cancer Cell, vol. 17, no. 1, pp. 98–110, 2010.
[38] H. Yang, F. Han, R. Hu et al., “PTEN gene mutations correlate
to poor prognosis in glioma patients: a meta-analysis,” Onco-
Targets and Therapy, vol. 9, pp. 3485–3492, 2016.
[39] J. A. Kraus, N. Glesmann, M. Beck et al., “Molecular analysis of
the PTEN, TP53 and CDKN2A tumor suppressor genes in
long-term survivors of glioblastoma multiforme,” Journal of
Neuro-Oncology, vol. 48, no. 2, pp. 89–94, 2000.
[40] J. Felsberg, B. Hentschel, K. Kaulich et al., “Epidermal growth
factor receptor variant III (EGFRvIII) positivity in EGFR-am-
pliﬁed glioblastomas: prognostic role and comparison between
primary and recurrent tumors,” Clinical Cancer Research,
vol. 23, no. 22, 2017.
[41] K. Liﬀers, K. Lamszus, and A. Schulte, “EGFR ampliﬁcation
and glioblastoma stem-like cells,” Stem Cells International,
vol. 2015, Article ID 427518, 11 pages, 2015.
[42] D. William, P. Mokri, N. Lamp et al., “Ampliﬁcation of the
EGFR gene can be maintained and modulated by variation of
EGF concentrations in in vitro models of glioblastoma multi-
forme,” PLoS One, vol. 12, no. 9, article e0185208, 2017.
[43] M. T. Stockhausen, H. Broholm, M. Villingshøj et al., “Mainte-
nance of EGFR and EGFRvIII expressions in an in vivo and
in vitro model of human glioblastoma multiforme,” Experi-
mental Cell Research, vol. 317, no. 11, pp. 1513–1526, 2011.
[44] A. C. deCarvalho, H. Kim, L. M. Poisson et al., “Discordant
inheritance of chromosomal and extrachromosomal DNA ele-
ments contributes to dynamic disease evolution in glioblas-
toma,” Nature Genetics, vol. 50, no. 5, pp. 708–717, 2018.
[45] B. Davis, Y. Shen, C. C. Poon et al., “Comparative genomic and
genetic analysis of glioblastoma-derived brain tumor-initiating
cells and their parent tumors,” Neuro-Oncology, vol. 18, no. 3,
pp. 350–360, 2016.
[46] C. Boccaccio and P. M. Comoglio, “The MET oncogene in
glioblastoma stem cells: implications as a diagnostic marker
and a therapeutic target,” Cancer Research, vol. 73, no. 11,
pp. 3193–3199, 2013.
[47] M. Bredel, D. M. Scholtens, A. K. Yadav et al., “NFKBIA dele-
tion in glioblastomas,” The New England Journal of Medicine,
vol. 364, no. 7, pp. 627–637, 2011.
[48] J. Lee, S. Kotliarova, Y. Kotliarov et al., “Tumor stem cells
derived from glioblastomas cultured in bFGF and EGF more
closely mirror the phenotype and genotype of primary tumors
than do serum-cultured cell lines,” Cancer Cell, vol. 9, no. 5,
pp. 391–403, 2006.
12 Stem Cells International
